Also trades as: 0HB0.L (LSE) · $vol 0M
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
1W: +3.8%
1M: +13.8%
3M: +8.6%
YTD: +39.9%
1Y: -12.2%
3Y: +77.9%
5Y: -17.0%
$38.03
+1.18 (+3.20%)
Weekly Expected Move ±7.6%
$31
$34
$37
$40
$43
Credit Risk of going bust: lower than 75% of companies Debt: 1.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 99.8%), Agios Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $31.2M against a stock market value of $2.27B.
Distance to default 8.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $15.6M (short-term plus half of long-term), stock volatility 57.8%; Altman Z'' 12.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.06 (down 99.8%), Agios Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $31.2M against a stock market value of $2.27B.
Distance to default 8.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $15.6M (short-term plus half of long-term), stock volatility 57.8%; Altman Z'' 12.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider—
Congress1 trades
ETF Holdings—
Key Statistics
Market Cap$2.3B
52W Range22.24-46
Volume738,982
Avg Volume1,129,625
Beta0.63
Dividend—
Analyst Ratings
Company Info
CEOBrian Goff
Employees540
SectorHealthcare
IndustryBiotechnology
IPO Date2013-07-24
Websiteagios.com
88 Sidney Street
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617 649 8600
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Latest News
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Is Agios Pharmaceuticals (AGIO) Undervalued On Hopes For A Mitapivat FDA Decision? - Simply Wall Street
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history - Yahoo Finance UK
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gheuens Sarah | M-Exempt | 500 | $25.01 | 2026-10-22 |
| Gheuens Sarah | S-Sale | 500 | $37.52 | 2026-10-22 |
| Gheuens Sarah | M-Exempt | 500 | $25.01 | 2026-10-22 |
| Gheuens Sarah | M-Exempt | 1,489 | $25.01 | 2026-10-21 |
| Gheuens Sarah | S-Sale | 1,489 | $37.53 | 2026-10-21 |